Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury.
Cao JY, Wang B, Tang TT, Wen Y, Li ZL, Feng ST, Wu M, Liu D, Yin D, Ma KL, Tang RN, Wu QL, Lan HY, Lv LL, Liu BC. · 2021
Read Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury. by Cao JY, Wang B, Tang TT, Wen Y, Li ZL, Feng ST, Wu M, Liu D, Yin D, Ma KL, Tang RN, Wu QL, Lan HY, Lv LL, Liu BC. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8039965.txt.
Introduction
Cao and co-authors test stem cell exosomes as a repair treatment for ischemic kidney injury. Exosomes from mesenchymal stem cells promise cell-free therapy for acute kidney injury. Where the vesicles go in the body, and how they heal, stayed unknown. The team used human umbilical cord stem cells as the source. Imaging tracked the vesicles in mice with ischemia-reperfusion injury.
The vesicles homed to the injured kidney and settled in proximal tubules. Surface proteins VLA-4 and LFA-1 guided that targeting. Treatment eased the injury in a dose-dependent way. Tubule cells escaped cell cycle arrest and apoptosis alike. The cargo molecule miR-125b-5p did the work by repressing p53. Blocking that microRNA erased the benefit. The study names both a vehicle and a mechanism.
Catalog record
| CREATOR | Cao JY, Wang B, Tang TT, Wen Y, Li ZL, Feng ST, Wu M, Liu D, Yin D, Ma KL, Tang RN, Wu QL, Lan HY, Lv LL, Liu BC. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury By Jing-Yuan Cao, Bin Wang, Tao-Tao Tang, Yi Wen, Zuo-Lin Li, Song-Tao Feng, Min Wu, Dan Liu, Di Yin, Kun-Ling Ma, Ri-Ning Tang, Qiu-Li Wu Published in: Theranostics DOI: 10.7150/thno.54550 ABSTRACT Mesenchymal stem cells-derived exosomes (MSC-exos) have attracted great interest as a cell-free therapy for acute kidney injury (AKI). However, the in vivo biodistribution of MSC-exos in ischemic AKI has not been established. The potential of MSC-exos in promoting tubular repair and the underlying mechanisms remain largely unknown. Methods: Transmission electron microscopy, nanoparticle tracking analysis, and western blotting were used to characterize the properties of human umbilical cord mesenchymal stem cells (hucMSCs) derived exosomes. The biodistribution of MSC-exos in murine ischemia/reperfusion (I/R) induced AKI was imaged by the IVIS spectrum imaging system. The therapeutic efficacy of MSC-exos was investigated in renal I/R injury. The cell cycle arrest, proliferation and apoptosis of tubular epithelial cells (TECs) were evaluated in vivo and in HK-2 cells. The exosomal miRNAs of MSC-exos were profiled by high-throughput miRNA sequencing. One of the most enriched miRNA in MSC-exos was knockdown by transfecting miRNA inhibitor to hucMSCs. Then we investigated whether this candidate miRNA was involved in MSC-exos-mediated tubular repair. Results: Ex vivo imaging showed that MSC-exos was efficiently homing to the ischemic kidney and predominantly accumulated in proximal tubules by virtue of the VLA-4 and LFA-1 on MSC-exos surface. MSC-exos alleviated murine ischemic AKI and decreased the renal tubules injury in a dose-dependent manner. Furthermore, MSC-exos significantly attenuated the cell cycle arrest and apoptosis of TECs both in vivo and in vitro. Mechanistically, miR-125b-5p, which was highly enriched in MSC-exos, repressed the protein expression of p53 in TECs, leading to not only the up-regulation of CDK1 and Cyclin B1 to rescue G2/M arrest, but also the modulation of Bcl-2 and Bax to inhibit TEC apoptosis. Finally, inhibiting miR-125b-5p could mitigate the protective effects of MSC-exos in I/R mice. Conclusion: MSC-exos exhibit preferential tropism to injured kidney and localize to proximal tubules in ischemic AKI. We demonstrate that MSC-exos ameliorate ischemic AKI and promote tubular repair by targeting the cell cycle arrest and apoptosis of TECs through miR-125b-5p/p53 pathway. This study provides a novel insight into the role of MSC-exos in renal tubule repair and highlights the potential of MSC-exos as a promising therapeutic strategy for AKI. INTRODUCTION Acute kidney injury (AKI) is a common syndrome defined by abrupt renal function decline. AKI occurs in approximately 10%-15% hospitalized patients and in even more than 50% intensive care unit patients 1,2. More importantly, AKI is an independent predictor of in-hospital mortality and has a high risk of progression to chronic kidney disease or end-stage renal disease for those survivors 1. Finding specific therapeutic strategies for established AKI is desperately needed 3. Renal ischemia/reperfusion (I/R) injury is a main cause of AKI, characterized by lethal and sublethal injuries of renal tubules 4. Researches have demonstrated that maladaptive and incomplete repair of renal tubules led to the progress of renal fibrosis 5, 6. Thus, protecting renal tubular epithelial cells (TECs) from ischemic insult and promoting tubular repair are critical for improving the outcomes of ischemic AKI 4, 7. Mesenchymal stem cells (MSCs), characterized by the abilities of self-renewal, differentiation, immunomodulation, and trophic support, are essential in regenerative medicine owing to the capacity to create a microenvironment conducive to the repair of injured tissues 8. Recently, a Phase 1a escalating clinical trial showed that autologous MSCs could not only increase blood flow and glomerular filtration rate, but also attenuate inflammation in post-stenotic kidneys 9. However, the short and long-term safety concerns of MSC-based therapy, for example, the risk of embolization, immunogenicity, and tumor formation, are the main obstacles for its clinical applications 10-12. Exosomes, a major class of extracellular vesicles (EVs) secreted by almost all kinds of cells, mediate intercellular communications by transferring bioactive molecules, such as mRNAs, non-coding RNAs, lipids, and proteins 13,14. It is worth noting that EVs derived from MSCs have been proposed as an alternative to MSC-based therapy for several diseases 15. In the previous study, we found that exosomes derived from MSCs (MSC-exos) could significantly attenuate cisplatin-induced murine AKI through inhibiting inflammation 16. Although the exact mechanisms are largely assumptive, anti-inflammation, anti-apoptosis, immunomodulation, and promoting proliferation are all conducive to the treatment of AKI 17. Exploring the underlying mechanism of MSC-exos in the treatment of AKI, especially for tubular repair, is crucial to the clinical application of this novel therapy. Numerous studies have proved that the enriched specific miRNAs of MSC-exos might account for the pro-repair effects in AKI and other diseases 3, 18. Wu et al. 19 suggested that miR-100-5p-abundant MSC-exos attenuated cartilage injury via inhibition of mammalian target of rapamycin in osteoarthritis. Duan et al. 20 found that adipose mesenchymal stem cell-derived EVs containing miR-26a-5p protected against diabetic nephropathy. In addition, depletion of miRNAs from EVs significantly weakened their regenerative potential in glycerol-induced AKI, suggesting the vital role of miRNA in the therapeutic effect of MSC-EVs 21. Consequently, the objective of this study was to examine the efficacy of MSC-exos in tubular repair and the role of specific miRNAs during this process. In this study, we demonstrated the biodistribution and therapeutic benefits of MSC-exos in murine ischemic AKI. MSC-exos were accumulated in the injured kidney, especially in proximal tubules, which was credited to the integrins on the surface of exosomes. Treatment with MSC-exos markedly ameliorated renal I/R injury through limiting the cell cycle arrest and apoptosis of TECs. Specifically, after profiling the exosomal miRNAs of MSC-exos by high-throughput miRNA sequencing (miRNA-seq), we demonstrated that MSC-exos exerted renal protective effect at least partially through miR-125b-5p/p53 signaling mediated tubular repair. Our findings strongly supported MSC-exos was an innovative therapeutic approach for tubular repair after AKI. METHODS Isolation and purification of MSC-exos Human umbilical cord mesenchymal stem cells (hucMSCs, donated by Wingor Biotechnology Co, Ltd) were cultured with media mixed with mesenchymal stem cell medium (ScienCell) and DMEM/F12 (Gibco), supplemented with 5% fetal bovine serum (FBS; ScienCell). The identification of hucMSCs was determined as previously described 16. To prepare MSC-exos, hucMSCs (Passage 2-6) were cultured with FBS-free media for 48 h, and the supernatants were subsequently collected for MSC-exos extraction. MSC-exos were isolated by gradient centrifugation and filtration 16. In brief, the supernatants were centrifuged at 2000×g for 20 min, 13,500×g for 30 min, filtrated with a 0.22-μm filter and ultracentrifuged at 200,000×g for 120 min (Beckman Coulter Optima L-80 XP) at 4 °C. The exosome pellets were resuspended in sterile phosphate buffer saline (PBS) and filtered using a 0.22-μm filter once again. Purified MSC-exos were resuspended in PBS and stored at -80 °C. Characterization of MSC-exos The morphology of MSC-exos was observed by transmission electron microscopy (TEM; HITACHI). The particle size and zeta potential 22 were detected by Nanoparticle tracking analysis (NTA; ZetaView PMX 110). Surface markers including exosomal markers (Alix, CD63, Tsg101, CD9), Golgi marker (GM130), and MSC-associated protein (CD44), were analyzed by Western blotting. Labeling of MSC-exos To obtain labeled MSC-exos, the donor hucMSCs were incubated with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine perchlorate (DiD; Invitrogen) or 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI; Invitrogen) and washed twice with sterile PBS to remove excess